Placido, P. D., Hughes, M. E., Weipert, C., Sammons, S. L., Morganti, S., Parsons, H. A., Abravanel, D., Giordano, A., Smith, K., Patel, A., Kirkner, G. J., Stever, C., Suggs, G. L., Sendrick, K., Snow, C., Winer, E. P., Tolaney, S. M., Lin, N. U., Jeselsohn, R. (2025). Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.1075